Quality initiative reduces unnecessary IV antihypertensive use for patients with severely elevated blood pressure
Retrieved on:
Thursday, June 15, 2023
IV, Prevalence, Oregon Health & Science University, Hypertension, New York City Department of Health and Mental Hygiene, NPO, Quality, Acute kidney injury, Hospital, BP, Editorial, Hospital medicine, MD, Patient, Patient safety, EHR, Division, SUNY Downstate Health Sciences University, Myocardial injury after non-cardiac surgery, Mouth, Pharmaceutical industry, Medical device, Medicine
Management with one-time doses of intravenous (IV) antihypertensives may increase adverse events such as acute kidney injury, myocardial injury or low blood pressure.
Key Points:
- Management with one-time doses of intravenous (IV) antihypertensives may increase adverse events such as acute kidney injury, myocardial injury or low blood pressure.
- Findings showed for ED-only encounters, IV hydralazine orders had a 49.5% reduction, IV labetalol orders a 30.1% reduction, and aggregate IV hydralazine and IV labetalol orders a 38.7% reduction.
- For inpatient encounters, IV hydralazine had a 22% reduction, IV labetalol orders a 6.3% reduction, and aggregate IV hydralazine and IV labetalol orders a 13.4% reduction.
- “By reducing unnecessary antihypertensive IV use, this low effort intervention likely had an impact on decreasing adverse events."